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Abstract: Background: The human papillomavirus (HPV) vaccination program for young girls aged
11–26 years was introduced in Switzerland in 2008. The objective of this study was to evaluate the
prevalence of high- and low-risk HPV in a population of undergraduate students using self-sampling
for monitoring the HPV vaccination program’s effect. Methods: Undergraduate women aged
between 18–31 years, attending the Medical School and University of Applied Sciences in Geneva,
were invited to participate in the study. Included women were asked to perform vaginal self-sampling
for HPV testing using a dry cotton swab. Results: A total of 409 students participated in the
study—aged 18–31 years—of which 69% of the participants were vaccinated with Gardasil HPV
vaccine and 31% did not received the vaccine. About HPV prevalence, 7.2% of unvaccinated women
were HPV 16 or 18 positive, while 1.1% of vaccinated women were infected by HPV 16 or 18 (p < 0.01).
Prevalence of HPV 6 and 11 was 8.3% in non-vaccinated women versus 2.1% in vaccinated women
(p < 0.02). We observed no cross-protection for the other HPV genotypes of a low- and high-risk strain.
Conclusions: Prevalence of HPV 6/11/16/18 was lower in vaccinated women versus unvaccinated
women. Continued assessment of HPV vaccine effectiveness in real population is needed.
Keywords: HPV; self-sampling; vaccination
1. Introduction
Cervical cancer is one of the leading causes of cancer-related death among women worldwide [1].
The development of cervical precancerous and cancerous lesions is a direct consequence of genital
human papillomavirus (HPV) infection, which has been identified as the most common sexually
transmitted infection in the world [2]. The introduction of HPV vaccinations represents a primary
preventive measure, which, if given to young girls prior to the onset of sexual activity, can potentially
alleviate the burden of the HPV infection [3]. Recent studies have predicted that cervical cancer rates
will be drastically reduced in about 10–15 years, thanks to the impact of the HPV vaccination and
HPV-based screening [4].
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In the United States, where the HPV vaccination was introduced in 2006, the population-based
sentinel surveillance system has shown that the prevalence of HPV-16/18 in cervical intra-epithelial
neoplasia grade 2 or worse (CIN2+) has decreased from 53.6% to 28.4% among women who have
received at least one dose of the vaccine [5]. Another trial conducted in England has found
HPV-16/18 prevalence to be reduced from 19.1% to 6.5% prior to and after the introduction of the
vaccine, respectively [6]. In Australia, monitoring surveillance demonstrated a very low prevalence
of vaccine-related HPV genotypes after eight years post-initiation of a national HPV vaccination
program [7].
About 300 women in Switzerland are diagnosed with cervical cancer annually, with a risk of 2
per 100 of dying from this disease. The HPV vaccination program for young girls aged 11–26 years
was launched in Switzerland in 2008 as a part of cervical cancer prevention, with the aim to prevent
cervical cancer and other HPV-related disease. The quadrivalent vaccine (targeting HPV16, 18, 6, and
11) is currently administered to girls aged 11–14 years, both in schools and in healthcare centers. While
it is known that the vaccination coverage rate varies widely among the different Swiss cantons, from a
minimum of 20% to as much as 60% of the target population, little is known about the vaccination’s
direct impact on the HPV infection rates. The differences in cantonal coverage rates can be explained
by the fact that each Swiss canton organizes the vaccination campaigns and the relative program on
its own, thus explaining the disparities and the lack of national coordination [8]. The lack of current
data on the impact of the HPV vaccination in the country, therefore, makes it difficult to monitor the
program’s efficacy.
The primary aim of this study was to evaluate the prevalence of high- and low-risk HPV
in a population of undergraduate students using self-sampling for HPV testing. The results of
this study will allow an estimation of the HPV vaccination program’s effectiveness, as well as the
acceptability of HPV self-sampling as a means to track down the infection among vaccinated young
girls in Switzerland.
2. Methods
2.1. Study Population and Setting
This study took place in the city of Geneva, which is situated in the canton of Geneva, Switzerland,
between January 2016 and October 2017. The enrolled participants were undergraduate nurse and
midwife students in their first, second, or third year of studies, as well as undergraduate students
attending their first through fifth year of Medical School at the University of Geneva (years 1 to 6).
All women aged 18–31 years were included; exclusion criteria were history of total hysterectomy or
having undergone cervical treatment in the past 12 months.
2.2. Study Procedure
Information about the trial was delivered through the University website and by the study
investigators, who sent an email to the target population describing the study and then delivered a
short presentation about the study after the main course’s classes.
The HPV self-collection kit was directly distributed to women who expressed an interest to
participate in the study at the end of class. The kit included a dry Dacron swab; a collection tube;
instructions with explanatory pictures for self-sampling; a flyer explanation about HPV infection,
cervical cancer screening, and cervical cancer; an informed consent form; and a questionnaire on
socio-demographics. Self-sampling was performed at home, and the kit, including both the swab and
filled-out questionnaire, was collected by the study investigators two to three days later. Additional
information about HPV and the test results were delivered by a designated study investigator upon
request. Sampling kits were provided free of charge.
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2.3. Data Collection
Each participant was asked to fill out a questionnaire reporting her socio-demographic
characteristics (age, nationally), sexual behaviors (number of sexual relations, use of
contraception/protection device), questions about HPV vaccination (number of doses received, name
of the vaccine), and questions about her acceptability of self-sampling.
2.4. Self-Sampling Procedure and Sample Preparation
Women were asked to gently insert the swab in the vagina, while being careful to avoid contact
with the external genitalia, and to carefully turn it up to five times either clockwise or counter-clockwise.
They were asked to then place the swab back into the dry tube, and to securely close it and put it back
into its plastic bag containing the rest of the kit’s material.
Each swab was then placed into a tube containing 3 mL of ThinPrep and vortexed for 45 s. A
total of 350 µL of the solution was then placed into a 5-mL, cone-shaped bottom tube (Eppendorf
Tube, Merck KGaA, Darmstadt, Germany). The samples were promptly sent to Buhlmann laboratories
for analysis.
2.5. Laboratory Analysis
DNA extraction was performed using the NIMBUS-IVD (Hamilton, Reno, Nevada) and the
extraction reagents StarMag (Seegene, Seoul, Korea). Amplification and detection was then performed
with the Anyplex™ II HPV high risk (HR) Detection (Seegene, Seoul, Korea) using the CFX96™
real-time thermocycler. Data recording and interpretation were automated. Anyplex II is a
semi-quantitative real-time multiplex PCR assay for screening and HPV genotyping. This test uses
dual priming oligonucleotides (DPO™) and tagging oligonucleotide cleavage and extension (TOCE™)
technologies and allows the simultaneous detection and genotyping of 19 high-risk HPVs (including
types 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 69, 73, and 82) and 9 low-risk HPVs (6, 11,
40, 42, 43, 44, 54, 61, and 70). As an internal control of assay validity, the β-globin gene is also detected.
By knowing the step at which the melting curve becomes positive, semi-quantification of the DNA
load of the β-globin and HPV genomes is made possible; this can vary from low (+; positive after 40
PCR cycles, <102 copies/reaction), to intermediate (++; positive within 31 to 39 PCR cycles, ≥102 and
<105 copies/reaction), to high (+++; positive before 31 PCR cycles, ≥105 copies/reaction).
Whenever the quantity of HPV genome was not high enough to be detected by the Anyplex II
device after running up to 40 PCR cycles, the test result was considered invalid. Analyses were run
twice before considering the test result as “invalid”.
2.6. Study Sample
Sample size was obtained based on estimated prevalence of 6% of HPV 16/18 infection in the
Swiss population aged less than 30 years. A total of 400 specimens would be needed to detect about an
85% reduction in HPV 16/18 prevalence (prevalence of 0.9% in the vaccinated population), given an
80% power and a two-sided significance level of 95%. Therefore, we estimate that a sample size of
400 women will be adequate for the analyses.
2.7. Statistical Analyses
Statistical analyses were run using STATA 13. Normality of the distribution was tested by the
Kolmogorov–Smirnov test. Descriptive statistics and frequencies were analysed for all variables.
Prevalence of HPV infections was evaluated for any HPV type, low vaccinated types (6 and 11), and
high-risk types (16 and 18). Low- and high-risk non-vaccine types were also evaluated. t-test and Chi
square test were used for the descriptive statistics and for the comparison between variables. A p value
of less than 0.05 was considered as statistically significant.
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A multivariate logistic regression was used to compare differences in HPV prevalence between
vaccinated and unvaccinated women. It was also performed to identify factors associated with HPV
prevalence and socio-demographic factors. The status of HPV infection (infected or not infected) was
used as the primary outcome. In multivariable models, only those covariates that were of a priori
interest of univariate analysis were included.
2.8. Ethical Approval
The study was approved by the Central Ethics Committee on Human Research of the Geneva
University Hospitals (approval number: 15-257). This study was conducted in accordance with the
Swiss law, as well as in accordance with the recommendations of Good Clinical Practices (ICH E6-1996)
and the Declaration of Helsinki (Fortaleza, Brazil, October 2013). The trial was registered under
cliniclatrials.gov with the identifiers: NCT03474211.
3. Results
3.1. Participants’ Socio-Demographic Characteristics
A total of 409 undergraduate students performed HPV self-sampling at home for HPV DNA
testing and filled out the given questionnaire, and were thus included in the study.
The participants’ baseline characteristics are presented in Table 1. The mean age was 24 years
(range 18–27); 55% of the participants were medical school undergraduate students (first to sixth year
of medical curriculum), the other 45% were nursing students or midwives in their first, second, or
third year of their Bachelor’s degree). The majority of the participants were Swiss (89%), 7% of them
came from France, and 3% came from other European countries or non-European countries (South
America or Africa).
A total of 80% of the participants were non-smokers and 8.6% smoked on a daily basis. Overall,
2.4% of the women reported never having had sexual intercourse; these women were nevertheless
included in data analyses.
Table 1. Study participants socio-characteristics. HPV—human papillomavirus.
Characteristic Study Population(n = 409)
n % or Mean 95% Confidence Interval
Age (mean years) 24 21.1 27.2
Recruitment site
Faculty of medicine 225 55.0% 50.2 59.8
School of health sciences 184 45.0% 40.2 49.8
Country of birth
Switzerland 365 89.2% 85.9 92
France 30 7.3% 5.1 10.2
Other European country 10 2.4% 1.2 4.3
other country 4 1.0% 0.3 2.3
Tobacco smoking
Yes, every day 35 8.6% 6.1 11.6
Yes, but not every day 45 11.0% 8.2 14.3
No, never 329 80.4% 76.4 84
Have you ever had sexual intercourse
Yes 399 97.6% 95.7 98.7
No 10 2.4% 1.2 4.3
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Table 1. Cont.
Characteristic Study Population(n = 409)
n % or Mean 95% Confidence Interval
Your age at your first sexual intercourse
(mean years)
Average 17 16.7 17.2
How many sexual partners did you have in your
life (mean number of partner)
Average 5.3 4.5 6.2
Do you use condoms as a means of
protection/contraception
Never 120 29.3% 22.7 31.4
Sometimes 90 22.0% 18.2 26.2
Often 100 24.4% 20.5 28.8
Always 99 24.2% 20.2 28.4
Have you been vaccinated against HPV
Yes 284 69.4% 64.8 73.7
No 125 30.6% 26.4 35.2
How many doses of HPV vaccine have you
received (only for vaccinated women n = 284)
One 20 7.0% 7.4 14.5
two 60 21.1% 16.7 26.2
Three 204 71.8% 66.4 76.8
Your age when you receive the first dose of the
HPV vaccine (mean years)
Average 14.8 14.2 15.6
Have you checked your vaccination record to
answer previous questions
Yes 220 53.8% 49 58.6
No 189 46.2% 41.4 51.1
In general, do you think that HPV vaccination is
a vaccination:
More important than others 14 3.4% 1.9 5.5
Less important than others 74 18.1% 14.6 22
As important as the others 321 78.5% 74.3 82.3
Would you recommend to your family/friends this
self-sampling as monitoring vaccination
Yes 367 89.7% 86.5 92.4
No 42 10.3% 7.6 13.5
In case of positivity of your self-collection, we
authorize you to contact you again
Yes 405 99.0% 97.6 99.7
No 4 1.0% 0.3 2.3
3.2. Vaccination Status
Overall, 69.4% of the participants were vaccinated with a minimum of one dose (284/409). Among
the vaccinated participants, 72% had received all three doses of the HPV vaccine, while 21% had
received two doses and 7% had received only one dose. All participants in our study were vaccinated
with Gardasil.
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A total of 75% of the vaccinated students were aged 18–23 years; the vaccination coverage rate
was not statistically different between the medical students and the nursing students or midwives (71%
versus 67%, respectively, p = NS). The mean age at the time of first vaccination dose was 14.8 years.
The majority of the participants (75%) reported that the HPV vaccination was as important as the other
vaccinations recommended in Switzerland, while up to 18% of them believed that this vaccination was
less important than other vaccinations recommended in Switzerland.
3.3. HPV Genotype Prevalence and Distributions
Figure 1 shows the genotype and prevalence distribution of HPV infection according to the
genotype. Overall, 31.1% (127/409) of the swabs were positive for the presence of HPV DNA.
Gardasil-targeted HPV genotypes were detected in 6.1% of the participants, who were positive for
HPV-16/18, while 6.8% of the women were positive for HPV-6/11. A total of 15% of the participants
were infected by multiple HPV genotypes. The prevalence of other HPV genotypes was 5.1 for HPV-31,
3.7% for HPV-33, 4.2% for HPV-45, and 2.7% for HPV-55.Int. J. Environ. Res. Public Health 2018, 15, x FOR PEER REVIEW    6 of 10 
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Figure 1. Human papillomavirus (HPV) genotype prevalence and distributions. In the case of multiple
genotypes, each genotype was counted independently.
Figure 2 presents the HPV prevalence of Gardasil-targeted genotypes; we found that 7.2% of
the unvaccinated population was HPV-16/18-positive, while only 1.1% of vaccinated women were
infected by HPV-16/18 (p < 0.001). The prevalence HPV-6/11 was 8.3% among unvaccinated women
versus 2.1% in the vaccinated group (p < 0.02). This difference was statistically significant for women of
all ages. Prevalence for other HPV high-risk strains was not statistically different between vaccinated
and unvaccinated women: 10.3% versus 11.2% p = NS.
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Figure 2. HPV prevalence 6/11 and 16/18, and other high-risk HPV according to vaccination status.
3.4. Relationship between HPV Infection and Sociodemographic
Table 2 reports the association between country of origin and HPV positivity. Non-Swiss women
had higher odds ratios of being HPV-positive than the participants who came from Switzerland,
(Adjusted OR (aOR) = 4.4 confidence interval (CI) 95% [1.3–7.6] and aOR = 3.8 CI 95% [2.4–4.1],
respectively). There was also a very strong association between sexual activity and HPV positivity, as
young women who reported having more than five different sexual partners throughout their sex life
had higher odds of being infected with HPV when compared with women who had only one sexual
partner aOR = 7.8 CI 95% [2.4–12.2]. Female students who sometimes used condoms were more likely
to be HPV-infected than those who reported always using condoms aOR 7.5 CI 95% [6.3–8.7], this
relationship was also found for those who never used a condom aOR 6.6 CI 95 % [4.8–8.2].
Table 2. Association between HPV positivity and socio demographic factor.
OR 95% CI Adjusted OR 95% CI
Recruitment site
Faculty of medicine 1 - 1 -
School of health sciences 1.3 0.9–1.7 1.4 0.9–1.8
Country of birth
Switzerland 1 - 1 -
France 1.2 0.5–1.9 0.9 0.3–1.6
Other European country 3.4 2.1–3.7 3.8 2.4–4.1
other country 4.9 1.7–8.1 4.4 1.3–7.6
Tobacco smoking
yes, every day 1.7 0.7–2.7 1.5 0.5–3.1
yes, but not every day 1.5 0.8–2.7 1.7 0.9–2.8
No, never 1 - 1 -
Have you ever had sexual intercourse
Yes 7.8 6.7–8.9 7.2 6.2–8.5
No 1 - 1 -
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Table 2. Cont.
OR 95% CI Adjusted OR 95% CI
How many sexual partners did you have in your life
(mean number of partner)
0 0.2 0.01–0.35 0.3 0.01–0.37
1 1 - 1 -
2–5 3.6 2.1–6 3.3 2.3–6.3
>5 9.8 5.4–14.2 7.8 2.4–12.2
Do you use condoms as a means of
protection/contraception
Never 6.3 4.7–7.9 6.6 4.8–8.2
Sometimes 7.9 6.8–9 7.5 6.3–8.7
Often 2.6 0.9–5.2 2.5 0.9–5.2
Always 1 - 1 -
Have you been vaccinated against HPV
Yes 11.2 7.1–15.2 8.9 5.9–13.2
No 1 - 1 -
How many doses of HPV vaccine have you received
One 1.4 0.7–2.1 1.5 0.7–2.1
two 1.1 0.3–1.9 1.3 0.5–2.2
Three 1 - 1 -
Statistically significant results in bold.
3.5. Acceptability of Self-Sampling
Overall, 100% of the participants accepted to repeat self-sampling in order to evaluate their HPV
clearance over time, and 85% of the participants reported that they would prefer self-sampling to the
conventional pap smear for cervical cancer screening in the near future (p = 0.001). A total of 76%
participants reported that self-sampling was not painful; only 8% found self-sampling very painful,
while 97% found that self-sampling was easy to use.
4. Discussion
In this analysis performed on self-collected home samples of undergraduate medical and
non-medical students, we found a low HPV prevalence of the Gardasil-targeted HPV genotypes.
The canton of Geneva vaunts one of the best immunization coverage rates in Switzerland, reaching
a target population coverage of nearly 80% [9]. One can assume that our results would have been
very different in a canton with low immunization rates, which can go as low as less than 20% of the
target population.
Our population constituted of future medical doctors, midwives, and nurses, and had a lower
vaccination rate than that of the general population [9]. This under-representation of the vaccination
rate among health professionals has been observed for other vaccines as well, such as the influenza
vaccine [10–12].
We found a statistically significant difference in the prevalence of high-risk genotypes (6/11/16
and 18) between vaccinated and unvaccinated young women. These findings confirm the results
of other studies on the effectiveness of the HPV vaccination as a means to decrease the prevalence
of vaccine-targeted HPV types [13–16]. On the other hand, we observed no cross-protection for the
other HPV genotypes, as we found no significant difference in the prevalence of non-Gardasil targeted
genotypes between vaccinated and unvaccinated women, similar to other studies on the subject [17,18].
Other studies, however, have questioned this non-cross-protection. Saccucci et al. have shown a
cross-protection in the first eight years after the HPV vaccine’s introduction in the United States in
2006 [19]. Another study assessing the effect of the introduction of the vaccine on the rates of infection
of non-vaccine HPV genotypes in community settings have demonstrated a possible cross-protection
effect [20,21], although the clinical significance of such phenomena is not yet fully understood, nor is
it sufficiently evidence-based to draw conclusions. Continuous monitoring of HPV genotypes, both
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vaccine-targeted and non-vaccine-targeted, is important to evaluate the possible cross-protection effect.
It is possible that, with the forthcoming of the nine-valent HPV vaccine in Switzerland, the prevalence
of other HPV genotypes in the population will drop.
Our results support the existence of associations between country of birth and number of sexual
partners with the likelihood of HPV infection. To reduce the impact of these risk factors on the
development of the relative sexually-transmitted infection, public health campaigns should be directed
toward promoting a greater population awareness about the HPV infection’s transmission, outcomes,
and primary measures of prevention.
The use of self-sampling to measure the prevalence, distribution of HPV genotypes, and HPV
vaccination effectiveness in our study population has proven to be effective. Moreover, a meta-analysis
on the subject has shown that when PCR-based assays that amplify DNA viral sequences are used,
the performance of HPV testing on clinician-collected samples is comparable to that of self-collected
samples, such as the ones used in the present study [22]. Self-sampling has been reported to be
more acceptable than physician-performed cytology testing, with women describing self-sampling
as far more comfortable and practical than clinician-based sampling, which systematically entails a
pelvic examination [23]. In our study, self-sampling proved to be a valid alternative to the standard
vaccination program monitoring, thus proving to be a rather promising public health tool to monitor
the effectiveness of HPV vaccination programs. Similarly, another study conducted in Canada has
found that this strategy was a valid alternative to physician-performed vaginal sampling to evaluate
the effectiveness of the HPV vaccination program [24,25].
5. Strength and Limitations
To our knowledge, this study was one of the first to directly assess the prevalence of HPV and
the effectiveness of the HPV vaccination directly in the population through the use of self-sampling
in Switzerland. The other studies carried out on the subject had a more modeling objective of the
prevalence of this infection after the introduction of the HPV vaccination in Switzerland without trying
to measure it directly in the population [26], but one large study with another methodology had shown
the same results in another Swiss county [27].
Another strength was represented by the fact that we used a real-time PCR to estimate the HPV
prevalence in the study population. In addition, as opposed to other trials using self-sampling, which
registered between 0.5 and 0.7% of unsatisfactory HPV test results, we had no invalid results.
This study has some limitations that need to be addressed. The population sample is constituted
exclusively of undergraduate students, which limits the generalization of our findings to other
populations or settings. Additionally, the study sample size was not powered to detect any potential
cross-protection of the vaccine-targeted HPV genotypes.
6. Conclusions
Our findings support the HPV vaccination’s effectiveness as a means to lower the prevalence
of the infection with most oncogenic genotypes in a population of young women. The decreasing
prevalence of the infection, therefore, represents one step closer to the prevention of the development
of cervical cancer, which is the vaccination’s long-term aim. As self-sampling was well accepted by
participants for monitoring the effectiveness of the HPV vaccination program, such a finding may
support the use of self-sampling for cervical cancer screening, in the view of alleviating the world
population from the burden of cervical cancer. In this study, we observed no cross-protection for the
other HPV genotypes—low- and high-risk strains—between vaccinated and unvaccinated women.
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